CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer

Cited by papers we hold 6

• Mechanisms of Polycomb group protein function in cancer · 2022
  No notice
• Recent advances in therapeutic strategies for triple-negative breast cancer · 2022
  No notice
• A review on the role of cyclin dependent kinases in cancers · 2022
  No notice
• Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence · 2022
  No notice
• Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes · 2021
  No notice
• The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.